Yuandong Biotech announced that the company plans to terminate the “biopharmaceutical research project”. The project originally planned to raise 129 million yuan. As of June 30, 2026, it had invested 28.3097 million yuan, and the remaining unused raised capital was 100 million yuan. The reason for termination was that the target drug had safety risks, the drug with a new mechanism was seizing the market, and the risk-benefit ratio of the project was low. The company plans to permanently supplement working capital with the remaining funds raised above, as well as interest and financial management income for daily production, operation and R&D activities. The matter has been reviewed and approved by the board of directors and still needs to be submitted to the shareholders' meeting for consideration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.